ROS1型
trk受体
医学
碱性抑制剂
癌症研究
血管生成抑制剂
内科学
肿瘤科
间变性淋巴瘤激酶
癌症
腺癌
肺癌
受体
神经营养素
恶性胸腔积液
作者
Alexander Drilon,Sai‐Hong Ignatius Ou,Byoung Chul Cho,Dong-Wan Kim,Jeeyun Lee,Jessica J. Lin,Viola W. Zhu,Hyeryun Kim,Tae Min Kim,Myung‐Ju Ahn,D. Ross Camidge,Jeehee Lim,Shanna Stopatschinskaja,Jingrong Jean Cui,David M. Hyman,Robert C. Doebele,Alice T. Shaw
标识
DOI:10.1200/jco.2018.36.15_suppl.2513
摘要
2513Background: Pts with ALK/ROS1/NTRK fusion-positive cancers can develop on-target TKI resistance [e.g. solvent front mutations (SFMs)] and/or central nervous system (CNS) relapse. Ropotrectinib ...
科研通智能强力驱动
Strongly Powered by AbleSci AI